- Novel treatment for alzheimer's disease
-
The present invention concerns a new pharmaceutical composition comprising an antagonist and a co-agonist of the N-methyl-D-aspartate-type glutamate receptor (NMDAR). The inventors found that the co-administration of these two compounds effectively inhibits production of amyloide-β peptide. In patient's suffering from Alzheimer's disease, these peptides are deposited in the extracellular matrix forming neuritic "plaques". Therefore, the present inventors identified a new possibility for prophylaxis and/or treatment of Alzheimer's disease by stopping the continued formation of neuropathological extracellular deposits.
- -
-
-
- METHODS OF TREATING CNS DISORDERS
-
The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.
- -
-
-
- Methods and compositions for treating amyloid-related diseases
-
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
- -
-
Page/Page column 140-141
(2010/11/24)
-
- Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
-
The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.
- -
-
-
- HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.
- -
-
-
- 1-Amino-alkylcyclohexanes as trypanocidal agents
-
Certain 1-aminoalkylcyclohexanes are anti-trypanosomiasis agents and trypanocides. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating trypanosomiasis therewith.
- -
-
-
- Synthesis and structure-affinity relationships of 1,3,5-alkylsubstituted cyclohexylamines binding at NMDA receptor PCP site
-
A series of 1,3,5-alkylsubstituted cyclohexylamines 2 were synthesized as ligands for the N-methyl-D-aspartate (NMDA) receptor phencyclidine (PCP) binding site. Pure diastereomers with defined configuration of amino group 2- ax and 2-eq were obtained. The optimal size of 1,3,5-substituents was determined for cyclohexylamines 2 with an equatorial amino group in the lowest energy conformation using Hansch analysis. According to the data, the lipophilic part of cyclohexylamines 2 does not discriminate between hydrophobic regions of the PCP binding site but rather recognizes this site as a whole lipophilic pocket. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
- Jirgensons, Aigars,Kauss, Valerjans,Kalvinsh, Ivars,Gold, Markus R.,Danysz, Wojciech,Parsons, Chris G.,Quack, Gunter
-
p. 555 - 565
(2007/10/03)
-